Nab-Paclitaxel vs Solvent-Based Paclitaxel Followed by Epirubicin Plus Cyclophosphamide for High-Risk HR+/HER2− Early Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial
Ann. Oncol 2023 Apr 14;[EPub Ahead of Print], O Gluz, S Kuemmel, U Nitz, M Braun, K Lüdtke-Heckenkamp, R von Schumann, M Darsow, H Forstbauer, J Potenberg, C Uleer, EM Grischke, B Aktas, C Schumacher, C Zu Eulenburg, R Kates, K Jóźwiak, M Graeser, R Wuerstlein, R Baehner, M Christgen, HH Kreipe, N HarbeckFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.